4 results
The aim of this study is to assess the safety and tolerability of oral administration of simvastatin plus rifaximin in patients with decompensated cirrhosis.
to evaluate the safety and efficacy of two different doses of a delayed release formulation of rifaximin (Rifaximin-EIR) for the prevention of recurrence of diverticulitis and diverticular complications in patients with a recent episode of…
To demonstrate superiority with regard to Progression Free Survival based on an Independent Review Committeeassessment of avelumab versus platinum-based doublet in NSCLC subjects with PD-L1+
The aim of this study is to assess the efficacy of oral administration of simvastatin plus rifaximin in patients with decompensated cirrhosis to halt the progression of the disease as assessed by prevention of the development of ACLF.